- Home
- HFFG vs IGMS Comparison
HFFG vs IGMS Comparison
Compare HFFG & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFFG
- IGMS
- Stock Information
- Founded
- HFFG 1997
- IGMS 1993
- Country
- HFFG United States
- IGMS United States
- Employees
- HFFG N/A
- IGMS N/A
- Industry
- HFFG Food Distributors
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- HFFG Consumer Discretionary
- IGMS Health Care
- Exchange
- HFFG Nasdaq
- IGMS Nasdaq
- Market Cap
- HFFG 100.2M
- IGMS 82.1M
- IPO Year
- HFFG N/A
- IGMS 2019
- Fundamental
- Price
- HFFG $3.92
- IGMS $1.22
- Analyst Decision
- HFFG
- IGMS Hold
- Analyst Count
- HFFG 0
- IGMS 8
- Target Price
- HFFG N/A
- IGMS $6.14
- AVG Volume (30 Days)
- HFFG 320.9K
- IGMS 167.6K
- Earning Date
- HFFG 05-07-2025
- IGMS 05-07-2025
- Dividend Yield
- HFFG N/A
- IGMS N/A
- EPS Growth
- HFFG N/A
- IGMS N/A
- EPS
- HFFG N/A
- IGMS N/A
- Revenue
- HFFG $1,201,667,000.00
- IGMS $2,679,000.00
- Revenue This Year
- HFFG $4.77
- IGMS $121.76
- Revenue Next Year
- HFFG $3.97
- IGMS $46.83
- P/E Ratio
- HFFG N/A
- IGMS N/A
- Revenue Growth
- HFFG 4.63
- IGMS 25.77
- 52 Week Low
- HFFG $1.70
- IGMS $0.92
- 52 Week High
- HFFG $4.93
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- HFFG 53.69
- IGMS 47.65
- Support Level
- HFFG $3.87
- IGMS $1.16
- Resistance Level
- HFFG $4.18
- IGMS $1.31
- Average True Range (ATR)
- HFFG 0.43
- IGMS 0.12
- MACD
- HFFG -0.11
- IGMS 0.03
- Stochastic Oscillator
- HFFG 17.89
- IGMS 76.92
About HFFG HF Foods Group Inc.
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, seafood, frozen and dry food, and non-food products to Asian restaurants and other food service customers throughout the United States. The Company's business consists of one operating segment; HF Group, which operates solely in the United States. The Company's customer base consists of Chinese and Asian restaurants, and it provides sales and service support to customers who mainly converse in Mandarin or Chinese dialects.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.